j.vandermolen
TL3 Regular · Catania, IT
Clinician. Posts general information only, and says so every time.
Joined 16 July 2024 · last posted 1d · groups: clinicians
124Posts here
3Topics
1Solutions
935Likes received
581Likes given
25Badges
264Days visited
3.2kPosts read
Recent activity
Full stream-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #90 · Start Here › Welcome · 27 Jul 2026 · 1 like Trust levels accumulate over time and they give you access to small things like the ability to edit your own posts without a timestamp. They are not a status symbol and…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #75 · Compounds › Retatrutide · 19 Jul 2026 · 1 like Glucagon receptor agonism seems paradoxical in a weight-loss compound because glucagon raises blood glucose. The paradox resolves because glucagon agonism also…
-
Why the Start Here categories exist, and what they are not for Replied, post #10 · Start Here › Welcome · 18 Jul 2026 · 3 likes Welcome. The orientation materials are pinned at the top of this category and they take about an hour. They answer most of the questions a new member has and they save…
-
Pooling trials with different estimands Replied, post #95 · Evidence › Meta-analyses · 13 Jul 2026 · 0 likes On post #91 — agreed on the reasoning, with one qualification. Study quality and weighting: some meta-analyses weight all studies equally; others weight by study size…
-
Reused chromatograms across lots: how to spot it Replied, post #57 · Analytics › COA interpretation · 13 Jul 2026 · 10 likes Water content (residual moisture) matters: lyophilised peptide is not dry. A few percent water is normal. The difference between a TFA salt and an acetate salt can be…
-
[2026 update] Travelling with an injectable: documentation and practicalities Replied, post #76 · Access › International · 13 Jul 2026 · 6 likes Currency and exchange rates: paying in different currencies has different costs and risks. Bitcoin eliminates currency and intermediary issues but has other risks.
-
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #58 · Compounds › Repair & healing peptides · 12 Jul 2026 · 3 likes Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do…
-
Named, unnamed and unspecified impurities as regulatory categories — the long version Replied, post #68 · Analytics › Impurities & related substances · 11 Jul 2026 · 14 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
Prior authorisation: what the criteria usually require — a second dataset Replied, post #11 · Access › Insurance & coverage · 9 Jul 2026 · 6 likes Appeals process: unemotional prose, the criterion quoted verbatim, evidence mapped to it point by point, dates, and nothing else. Describing how the decision affected…
-
AOD-9604 and the fragment hypothesis, revisited — does this still hold? Replied, post #11 · Compounds › Other compounds · 8 Jul 2026 · 3 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #13 · Practice › Interactions · 5 Jul 2026 · 0 likes Coming back to post #11, because the follow-up matters more than the original answer. Having read the exchange above, I think I was wrong earlier in this topic and I…
-
Restarting after a long gap: what the labelling implies Replied, post #12 · Practice › Dosing & titration · 5 Jul 2026 · 0 likes Picking up post #9: that is the part I would want checked first. Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose…